Tag: Infusion reactions

Ocrevus (ocrelizumab) is an effective treatment for relapsing and primary progressive multiple sclerosis (MS), but it is not suitable for everyone. There are several critical situations and pre-existing conditions where this powerful medication should be avoided to prevent severe health complications.

According to a 2021 case report in the *Journal of Medical Case Reports*, severe cardiovascular toxicity, including cardiac arrest, is a rare but documented risk associated with rapid intravenous vancomycin administration. This article explores the mechanisms behind how vancomycin can cause heart problems, focusing on infusion-related reactions, and outlines the preventative measures used to ensure patient safety.

While remdesivir has been vital in treating COVID-19, with clinical trials showing improved recovery times for some patients, its use requires careful consideration of the potential for severe adverse reactions. This article explores **what are the severe side effects of remdesivir** and the important monitoring steps healthcare providers take to ensure patient safety.

According to clinical trial data, the most common adverse reactions reported in at least 10% of patients treated with nipocalimab breakthrough therapy designation BTD were respiratory tract infection, peripheral edema, and muscle spasms. This FcRn inhibitor is under evaluation for several autoimmune and alloimmune conditions, making a review of its safety profile essential.

In clinical trials for multiple sclerosis (MS), Tysabri (natalizumab) was associated with common side effects, with headache reported by 38% of patients and fatigue affecting 27%. Understanding **what are the most common side effects of Tysabri** is essential for patients, who must enroll in the mandatory TOUCH program due to the risk of a rare but serious brain infection.

The FDA has issued multiple serious, or 'boxed', warnings for rituximab due to significant adverse event reports. The most important safety information includes risks of fatal infusion reactions, progressive multifocal leukoencephalopathy (PML), and hepatitis B virus (HBV) reactivation.

According to clinical data, most infusion-related side effects with Rituxan occur within 30 to 120 minutes of the first infusion and are typically mild and temporary. However, the duration of Rituxan side effects varies significantly depending on the type of reaction, with some symptoms resolving within hours while others can persist for weeks, months, or even longer.

Infusion-related reactions are a very common side effect of Rituxan, with some studies showing they occur in over 80% of patients during the first infusion [1.6.5]. So, what is the most common side effect of Rituxan and what should patients expect?

The infusion time for Nexviazyme, an enzyme replacement therapy for Pompe disease, can vary significantly among patients, typically lasting several hours depending on dosage and individual tolerance. This intravenous treatment is administered incrementally, with initial infusions often taking longer than subsequent ones. Understanding the factors influencing **how long is a Nexviazyme infusion** is crucial for patients and their caregivers in planning their treatment schedules.

Though practices vary, many hospitals administer premedications like diphenhydramine (Benadryl) and acetaminophen before an IVIG infusion. So, **why is Benadryl given before IVIG?** It's a key strategy to prevent or mitigate infusion-related adverse reactions, enhancing patient tolerance and safety.